Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Annals of the Rheumatic Diseases|August 31, 2015
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapyJung-Yoon Choe, Nenad Prodanovic, Jaroslaw Niebrzydowski, et al.
The Journal of Clinical Endocrinology and Metabolism|September 7, 2024
Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12Bente Langdahl, Yoon-Sok Chung, Rafal Plebanski, et al.
Rheumatology and Therapy|April 29, 2021
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 StudyPhilip J Mease, Apinya Lertratanakul, Kim A Papp, et al.
Bone|December 14, 2024
SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trialYoon-Sok Chung, Bente Langdahl, Rafal Plebanski, et al.
Annals of the Rheumatic Diseases|July 4, 2025
Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b studyAlan Kivitz, Xenofon Baraliakos, Elena Tomaselli Muensterman, et al.
Annals of the Rheumatic Diseases|March 24, 2019
Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa studySudha Visvanathan, Stefan Daniluk, Rafał Ptaszyński, et al.
Annals of the Rheumatic Diseases|June 2, 2025
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyPeter C Taylor, Philip J Mease, Kurt de Vlam, et al.
Lancet (London, England)|July 31, 2017
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trialBente L Langdahl, Cesar Libanati, Daria B Crittenden, et al.
Pageof 3